retatrutide trial status Diabetes Dialogue: Reduces Body Weight 28.7% in Phase 3 Medscape | Retatrutide, Eli Lilly's

FDA prescribing information lists the most frequent adverse reactions to Ozempic, reported in at least 5% of treated patients, as nausea, vomiting, diarrhea, abdominal pain, and constipation

Methods This study was analytical observational with cross-sectional approach

Both partners should be encouraged to optimize overall health, maintain achieved weight loss through lifestyle measures, and work closely with their healthcare teamincluding reproductive specialists when indicatedto ensure the safest approach to family planning while managing chronic metabolic conditions

Patients should not attempt to obtain retatrutide or any other unlicensed injectable medicine through online or unregulated sources, as the safety, quality, and authenticity of such products cannot be assured